Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director · President, CEO | February 10, 2022 | February 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date February 10, 2022 · Filed February 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.44 · Expires 2032-02-09 | Direct | 200,000 |
Reported balance
After 2022-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-10 · Grant · Acquired 200,000 · Balance 200,000 F1: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2023, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F2: In addition to the remaining options to purchase 200,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2023, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F2: In addition to the remaining options to purchase 200,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2018 Filed Dec 13, 2018 01:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 8,324 | $72.88 | $606,618.16 |
DisclosureSEC source: 0001209191-18-062336 · doc4.xml · nonDerivative · entry 9 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,064 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.52 to $73.04 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 01:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 9,673 | $71.92 | $695,717.95 |
DisclosureSEC source: 0001209191-18-062336 · doc4.xml · nonDerivative · entry 8 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,388 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.51 to $72.48 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 01:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 12,003 | $71.11 | $853,480.52 |
DisclosureSEC source: 0001209191-18-062336 · doc4.xml · nonDerivative · entry 7 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,061 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.51 to $71.49 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 01:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 30,000 | $1.12 | $33,600.00 |
DisclosureSEC source: 0001209191-18-062336 · doc4.xml · nonDerivative · entry 6 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 01:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 4,998 | $70.83 | $354,008.34 |
DisclosureSEC source: 0001209191-18-062336 · doc4.xml · nonDerivative · entry 5 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,064 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,587 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-18-062336 · doc4.xml · derivative · entry 10 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,361 Underlying: Common Stock · 30,587 shares Expires 2021-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 4,964 | $72.48 | $359,805.12 |
DisclosureSEC source: 0001209191-18-062336 · doc4.xml · nonDerivative · entry 4 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,062 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.13 to $73.07 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 10,347 | $71.49 | $739,700.82 |
DisclosureSEC source: 0001209191-18-062336 · doc4.xml · nonDerivative · entry 3 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,026 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.01 to $71.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 15,276 | $70.57 | $1,078,082.31 |
DisclosureSEC source: 0001209191-18-062336 · doc4.xml · nonDerivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,373 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.01 to $71.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 30,587 | $1.12 | $34,257.44 |
DisclosureSEC source: 0001209191-18-062336 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 21:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,208 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001209191-18-042363 · doc4.xml · derivative · entry 4 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,208 shares Expires 2021-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 21:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,428 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-18-042363 · doc4.xml · derivative · entry 3 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,428 shares Expires 2020-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 21:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,208 | $1.61 | $9,994.88 |
DisclosureSEC source: 0001209191-18-042363 · doc4.xml · nonDerivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 21:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 1,428 | $2.24 | $3,198.72 |
DisclosureSEC source: 0001209191-18-042363 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 20:38 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 22,428 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001209191-18-036984 · doc4.xml · derivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,428 shares Expires 2018-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 20:38 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 22,428 | $2.59 | $58,088.52 |
DisclosureSEC source: 0001209191-18-036984 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (right to buy) · Derivative | 63,000 | $0.00 Strike: $106.84 | $0.00 |
DisclosureSEC source: 0001209191-18-005995 · doc4.xml · derivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2028-01-25 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on January 26, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:40 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $24.60 | $0.00 |
DisclosureSEC source: 0001209191-17-015443 · doc4.xml · derivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2027-02-23 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 24, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:44 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries D Preferred · Derivative | 2,020 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006402 · doc4.xml · derivative · entry 4 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,020 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:44 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries C-1 Preferred · Derivative | 781 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006402 · doc4.xml · derivative · entry 3 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 781 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:44 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries C Preferred · Derivative | 2,197 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006402 · doc4.xml · derivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:44 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionCommon Stock | 4,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006402 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.